Krystal Biotech, Inc.

US$300.88As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:KRYSHealthcare
Country USA
PE (Fwd) •••
TSR 9Y CAGR 45.38%
Div yield —
ROE 17.50%
Biotechnology
Beta (5Y) 0.65
PE TTM 40.87
TSR TTM 52.34%
Mkt cap US$8.916B
ROIC 37.54%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$288
(4.30%)
(80.05%)
Hold 2|9|1|1|8
4Q25
1Q26
2Q26
3Q26
Earnings per share$
5.11
5.61
5.34
5.13
15.65%
33.27%
15.94%
7.98%
Revenue$M
462.4
465.6
486.1
496.0
7.55%
5.77%
8.28%
5.42%
Peers (US$8.916B)
Cap (US$)
PE
9.152B
—
Capital
TTM
5Y
10Y
Leveragex
0.625
(0.889)
(0.651)
EBIT/Intx
2.066
0.683
0.491
Own earn%
2.73
(11.99)
(16.89)
Sh yield%
31.03
58.41
57.54
Owners
Insiders/Inst%
10.23
69.86
Short interest%
5.32
SBC / revenue%
0.54
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
8
Op margin range%
22–27
$1 testx
—
Incr. ROIC%
4